Metis Precision Medicine
Turin
About Metis Precision Medicine
Metis Precision Medicine is a B-Corp founded with the vision of bringing powerful cancer therapies to patients in need. Metis owns the intellectual property of a suite of anti-Met monoclonal antibodies (mAbs), with different and unique mechanisms of action, and is currently seeking investors, biotech or pharmaceutical companies interested in acquiring the relevant platform technology on a global basis.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $1.5M
- Funding stage: Seed
- Last round: Secondary Market (Mar 2022)
- Website: metisprecisionmedicine.org
- Phone: 11710450013
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Precision Medicine
Social Profiles
Canonical: https://fsome.com/organization/metis-precision-medicine-161314 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.